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Background: Worldwide, substantial proportions of women suffer from postmenopausal osteoporosis and would benefit from 
bisphosphonate treatment. However, variations in patient characteristics may affect therapeutic responses. The MOBILE study 
demonstrated the comparable efficacy of once-monthly (50+50mg, 100mg or 150mg) and daily (2.5mg; 3-year vertebral fracture 
risk reduction: 62%1) oral ibandronate in 1,609 women (aged 55–80 years and ≥5 years since menopause) with osteoporosis 
(lumbar spine bone mineral density [BMD] T-score <–2.5 and ≥–5).2,3 A pre-specified analysis explored the influence of baseline 
patient characteristics on the relative efficacy of once-monthly and daily oral ibandronate for improving lumbar spine BMD over the 
2-year treatment period. 
Methods: The influence of the following baseline patient variables on treatment outcomes was assessed: BMD, fracture history 
and age (Table). All analyses involved at least 20% of the overall study population. Increases in lumbar spine BMD (L2–L4) were 
compared across groups by a post-hoc non-inferiority test (using the pre-defined overall non-inferiority margin of 1.3%). 
Results: Sizeable gains in lumbar spine BMD were observed in all treatment arms and all patient subgroups (Table). In all 
analyses, increases in the 100mg and 150mg monthly arms were numerically greater than in the daily arm (Table). In all but a 
single monthly subgroup (50+50mg and aged >70 years; Table), non-inferiority to the daily group was indicated based on a lower 
limit of the 95% confidence interval (CI) for the difference in mean lumbar spine BMD change ≥–1.3%. 
 
Mean change (%, 95% CI for difference vs daily) in lumbar spine BMD at 2 
years.
2.5mg 50+50mg 100mg 150mg
Overall population 5.0 5.3 [–0.34, 1.13] 5.6 [–0.14, 1.35] 6.6 [0.84, 2.31]
Baseline BMD <–2.5 to ≥–3.0 4.5 5.2 [–0.43, 1.79] 4.8 [–0.89, 1.38] 6.5 [0.84, 3.07]
Baseline BMD <–3.0 to ≥–3.5 4.5 4.9 [–1.05, 1.67] 5.9 [–0.12, 2.63] 5.7 [–0.37, 2.43]
Baseline BMD <–3.5 to ≥–5.0 5.8 5.9 [–1.24, 1.56] 6.1 [–1.05, 1.77] 7.3 [0.14, 2.86]
No previous fracture* 5.0 5.3 [–0.77, 1.23] 5.5 [–0.63, 1.41] 6.4 [0.29, 2.31]
Previous fracture* 4.8 5.3 [–0.43, 1.75] 5.7 [–0.19, 2.03] 6.7 [0.77, 2.94]
Age <70 years 4.6 5.2 [–0.26, 1.47] 5.3 [–0.13, 1.61] 6.4 [0.94, 2.67]
Age ≥70 years 5.8 5.7 [–1.56, 1.27] 6.2 [–1.17, 1.73] 6.8 [–0.37, 2.42]
 
 
*since age 45 
Conclusion: Independent of clinically relevant baseline characteristics, once-monthly oral ibandronate dosing produces 
comparable increases in BMD to an efficacious daily oral ibandronate regimen. 
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